Melatonin's phase-shifting effects in humans are thought by some investigators to be subtle, particularly in comparison to those achieved with appropriately timed bright light exposure. The initial study in sighted people was only intermittently successful in phase advancing the endogenous melatonin profile. The study of free-running blind people showed statistically significant phase advances the day after melatonin administration. When holding the light-dark cycle constant, consistent phase advances the day after melatonin administration in sighted people were first shown in the course of describing the melatonin phase response curve (PRC), which also provided the first evidence that melatonin could cause phase delays. More recent studies have replicated the PRC and shown that phase shifts can occur in response to physiological doses within 1 day. This article reviews this literature and attempts to reconcile some of the results from differing studies. If the timing of melatonin administration is optimized according to the melatonin PRC, then consistent phase advances and delays can be achieved. If a reliable and sensitive circadian phase marker (e.g., the highly resolved dim light melatonin onset) is used, then phase shifts can be demonstrated consistently&mdash;even a small shift the day after a single physiological dose. The present authors predict that in the near future, melatonin administration will become as useful as bright light exposure in the treatment of circadian phase disorders.
Introduction
That exogenous melatonin administration might be able to phase advance the endogenous melatonin profile was first suggested by Arendt and coworkers (Arendt et al., 1985) . For 1 month in the spring, 12 subjects were administered 2 mg of melatonin that ceased the day before assessment of the endogenous melatonin profile. It was given at 1700 h, 8 h before the peak of the endogenous profile. No tabulation of the data was provided, and there was no statistically significant phase-shifting effect. However, 2 or 3 subjects were reported to show phase advances (Arendt et al., 1985; Wright et al.,1986) .
The study was repeated in the autumn on all but 1 of the subjects. In the repeat study, the melatonin profile was assessed on the final day of 3 weeks of exogenous melatonin administration. Unfortunately, in the repeat study, a discernible endogenous melatonin profile could not be observed in 7 subjects, due mainly to the confounding presence of exogenous melatonin levels. The other five subjects, however, were reported to advance by 1 to 3 h, and no phase delays were found. There were no tabular data, and the results were not statistically significant. For the entire group, the average melatonin offset (the most discernible part of the posttreatment profile) appeared to be at the same time before and after treatment (Wright et al., 1986) .
The earliest attempt to demonstrate melatonin's phase-delaying effects in humans was considered unsuccessful (Arendt et al., 1985; Wever, 1989) . In a collaborative study with the Arendt group, Wever gave 5 mg daily 1 h before bedtime in a fractional desynchronization protocol (in which the light-dark [LD] cycle was lengthened by 10 min per day from a period of 26 to 29 h). With the exception of self-rated fatigue and alertness, there were no effects on any of several circadian phase markers including the melatonin rhythm. Some of these findings constituted the first evidence that melatonin could perhaps intermittently phase advance the endogenous melatonin profile while holding the LD cycle constant. It also would be reasonable to conclude from these studies that, to whatever extent phase-advancing effects occur, they abate the day after withdrawal of exogenous melatonina finding that has not been replicated by subsequent studies.
The Claustrat group (Mallo et al.,1988) assessed the endogenous melatonin profile after 1 and 3 days of withdrawal from 4 days of melatonin (8 mg) administered at 2200 h to 6 subjects. The investigators noted that the peak of the exogenous pulse probably was 4 h ahead of the endogenous profile's acrophase. The average acrophase on the day after administration was not statistically significantly different from baseline, although a statistically significant phase advance was found 3 days after withdrawal. The latter finding was the first to demonstrate statistically significant phase-advancing effects of melatonin in sighted people. Although this type of response latency might be explained by animal studies in which phase advances require a few transient days before they are fully manifested, transients in animal studies are observed under constant dim light conditions; in the Claustrat group study (Mallo et al.,1988) , the LD zeitgeber that continues past melatonin withdrawal would be expected to resist further phase shifts. No further studies have been done that have replicated the time course of this study The next investigation of the phase-shifting effects of melatonin in sighted people was in air travelers (Arendt et al.,1987) . However, in the jet lag paradigm, phase shifting occurs in response to the new LD cycle. Melatonin administration, particularly at times and in doses that could be soporific, might speed adaptation by imposition of darkness (when the eyes are closed during sleep) on the perceived LD cycle.
The Human Melatonin Phase Response Curve
Because of the preceding studies, we were concerned that exogenous melatonin might not be able to sufficiently override the LD zeitgeber so as to demonstrate a robust, consistent, statistically significant phase-shifting effect the day after administration. Therefore, our first study of melatonin's phase-shifting effects on the endogenous melatonin profile was in free-running blind people (Lewy and Newsome, 1983) . In addition to testing the phaseshifting effects of melatonin in the absence of the competing or confounding influence of the LD cycle, we were interested in treating their recurrent sleep disorders. We were impressed by Redman et al.'s (1983) study in which rats that were free running in constant dim red light were entrained to a daily injection of melatonin. Using a dose of 5 mg administered daily at 2200 h for 3 weeks, we found that melatonin produced phase advances of about 24 min per day . However, we have been able to document entrainment to a daily dose of melatonin in only 1 blind person (see Sack and Lewy, 1997 [this issue]).
After obtaining these results, it occurred to us that a highly resolved melatonin phase marker in sighted people might facilitate demonstration the day after melatonin administration of expectedly smaller phase shifts. Consequently, we undertook a study of the effects of melatonin on the endogenous dim light melatonin onset (DLMO). As discussed later, the DLMO is a very practical and reliable circadian phase marker (Lewy and Sack, 1989) . Melatonin (0.5 mg) was administered as a split dose to 8 subjects at 1700 and 1900 h for 4 days. This dose was considerably lower than previously used and was chosen to be able to apply the results to the question of endogenous melatonin's function. In each 2-week trial, capsules were taken every day except the day of DLMO determination. During the lst week, placebo capsules were administered for 6 days, followed by a baseline (pretreatment) DLMO. Placebo capsules also were administered the 1st 2 days of the 2nd week. Subjects slept at home and were asked to maintain a consistent sleep-wake cycle.
The average phase shift was 28 min and was statistically significant (p <_ .01). There was considerable interindividual variability in the phase-shift response. There also was marked interindividual variability in the baseline (pretreatment) DLMO. (However, intraindividual variability in the DLMO was quite low; the standard deviation was less than the sampling interval of 30 min, which is less than the standard deviation of the fitted core body temperature maximum assessed under a constant routine [Brown and Czeisler, 1992] .)
We found that there was a linear relationship between the time of melatonin administration relative to the pretreatment DLMO and the resulting phase advance (Fig. 1 ). The data resembled the portion of a phase response curve (PRC) comprising the latter part of the advance zone and the beginning of the &dquo;dead zone.&dquo; Therefore, we decided to administer melatonin at other times of the day and night. We expanded this study to include 9 subjects (8 males, 1 female), aged 20 to 48 years, who were involved in a total of 30 trials (Lewy et al., 1992) . Except for three data points that occurred during sleep, melatonin was administered as a split dose. The average wake-up time was 0642 h, and the average baseline DLMO was at 2055 h. The data were plotted according to circadian time (CT).
Because the DLMO on average occurs about 14 h after sleep offset (lights on), it is designated CT 14 no matter what clock time it occurs.
The data appear in Fig. 2 . The linear relationship between time of administration in the afternoon and evening and the magnitude of the phase-advance shift continued to be present. Earlier administration times were associated with decreasing phase-advance magnitudes. In the late night and morning, there were six data points that showed phase delays. There also appeared to be a small dead zone of reduced responses shortly after the time of the endogenous melatonin onset. The crossover time between delays and advances occurred around CT 4, and between advances and delays occurred from CT 14 to 18. The data described a PRC that is about 12 h out of phase with the PRC to light. A more detailed analysis of the phase Figure 1 . Phase shifts after melatonin administration, demonstrating a linear relationship between the circadian time (CT) of melatonin administration and the magnitude of phase advance. Each data point represents 1 subject. Data represented by the closed squares are from the first 8 subjects in the original phase response curve study (see Fig. 2 ). CT of administration was calculated using the time of the first capsule in relation to the pretreatment dim light melatonin onset, which is designated CT 14. The open squares represent data we plotted from Mallo and colleagues (1988) ; these data are the phase shifts of 6 subjects 3 days after being given 8 mg melatonin at 2200 h for 4 days. Pre-and posttreatment endogenous melatonin acrophases were converted from degrees to hours (1 h = 30°), the baseline melatonin onset was estimated to be 5.5 h before the melatonin acrophase, and then CT of administration in relation to the pretreatment melatonin onset was calculated. relationship between the two PRCs is discussed elsewhere (Lewy et al., in press-a).
The melatonin PRC may even be important for understanding data from prior studies. Although the time courses of phase shifting in the original European studies remain discrepant and unexplained (Arendt et al., 1985; Mallo et al., 1988) , the melatonin PRC predicts that administration earlier in the afternoon would have resulted in more consistent and robust phase-advance shifts on the day following withdrawal of exogenous melatonin. It also is important, when using the endogenous melatonin profile as a circadian marker in sighted people, to obtain samples under dim light (< 30 lux) that precedes the first sample by about 1 h and continues throughout sampling so as to avoid suppression of endogenous melatonin by light (Lewy et al., 1980) . Optimally, the sampling interval should be at least 30 min within a window around the Figure 2 . Phase shifts in the dim light melatonin onset as a function of circadian time (CT) for 9 subjects (a total of 30 trials), providing the first evidence for a human melatonin phase response curve. Each of the 9 subjects has a separate symbol. CT of administration was calculated using the time of the first capsule. In preparing this review, we took the opportunity to analyze more carefully the original European data. In so doing, we found the same type of evidence for a portion of a PRC in the Claustrat group study (Mallo et al., 1988) as we found in our first 8 sighted subjects. If the phase shift obtained 3 days after withdrawal is plotted against the time of administration relative to the endogenous melatonin profile, a highly linear relationship is revealed. These results appear in Fig. 1 . This regression line is as linear as the one that caused us to investigate the other portions of the melatonin PRC. Remarkably, the correlation coefficients were exactly the same for both studies (and both correlation coefficients were statistically significant [p <.01]. (The slope of the Claustrat group regression line is steeper despite the later administration times, most likely because the dose was 16 times greater [Mallo et al., 1988] .)
The data in the Arendt et al. (1985) article are not easily quantifiable. However, the melatonin PRC offers an alternative (but not mutually exclusive) explanation for why phase advances were found in the 5 subjects who manifested them. One explanation, provided by the investigators, was that all patients with a clearly discernible posttreatment endogenous melatonin profile manifested a phase advance; that is, a posttreatment profile is discernible from the exoge-nous pulse when the pulse precedes the profile by a sufficiently long interval such that exogenous levels fall before the endogenous offset and preferably before the endogenous onset. Another explanation, however, is that an earlier administration time relative to the endogenous profile would, according to the melatonin PRC, more likely cause a phase advance. Finally, the negative result in the collaborative study between Wever (1989) and Arendt et al. (1985) is now understandable. Most likely, melatonin was administered on the advance zone of the melatonin PRC, when only a phase delay would have increased the range of entrainment. The preceding examples demonstrate that the melatonin PRC is a useful tool for understanding both positive and negative results of studies on the phase-shifting effects of melatonin.
Replications of the Human
Melatonin Phase Response Curve
The melatonin PRC was, to a large extent, replicated by the Claustrat group, who administered melatonin in a truly physiological dose intravenously for 3 h (Zaidan et al., 1994) . Although there were only four time points for this PRC, the results were very interesting. First, phase shifts were observed within the first 24 h following a single physiological dose, suggesting that phase shifting began almost immediately Second, there was a remarkable similarity to the original PRC, particularly given the differences in dosing regimens and the difficulties encountered when trying to discern the endogenous melatonin profile from exogenous melatonin levels. A third interesting result of this study was that at least one dose regimen affected the area under the curve (AUC) of the posttreatment endogenous melatonin profile. Perhaps this can explain some of the early discrepant results (Arendt et al.,1985; Mallo et al.,1988) , and future studies should be designed with this phenomenon in mind. However, these effects appear to be minimal, if not nonexistent, the day following withdrawal of melatonin (Matsumoto et al., 1997) .
Following publication of the Claustrat group's melatonin PRC, the Arendt group made another significant contribution when those researchers published their dose response curve showing a log-linear relationship between the dose of melatonin and the magnitude of phase shifts in the DLMO for doses of 0.05, 0.5, and 5 mg (Deacon and Arendt, 1995) . (Data that we have collected on smaller numbers of subjects over the years are consistent with the Arendt group's dose response curve.) The Arendt group also found that a measurable phase shift occurs 1 day after a single dose. (Radioimmunoassay methodology has improved such that the DLMO is now commonly used as a circadian phase marker that can reveal even very small shifts.)
The original PRC contained only six data points in the delay zone (Lewy et al., 1992) . Indeed, some investigators were not convinced that melatonin could cause phase delays, whereas others thought that it was easier to cause a phase advance than a phase delay (Zaidan et al., 1994) . Consequently, we undertook to replicate it. In the replication study, we administered 0.5 mg as a single dose. Each subject participated in 12 trials in which administration times were selected at intervals of approximately 2 h. In this study, a pre-baseline DLMO was included that preceded the placebo week. So far, 6 subjects (5 females, 1 male) have completed the study (aged 27-77 years, mean age = 54).
The new PRC is remarkably similar to the original. There are many more delay responses at the expected times (Lewy et al., in press-a). The binned data appear in Fig. 3 along with the binned data of the original PRC. Similar to what was observed previously, the crossover time between advances and delays is at about CT 18 and the crossover time between delays and advances is at about CT 6. There are some differences between the new PRC and the original that are worth discussing. Advance responses continue somewhat after CT 14. This adds support for our hypothesis that a function of endogenous melatonin in humans is to augment entrainment of the endogenous circadian pacemaker by the LD cycle (Lewy et al., 1992; Lewy et al., 1991) . This hypothesis is supported because it is now clear that light exposure at or slightly after the DLMO will acutely suppress melatonin production so as to delay it, thereby reducing stimulation by endogenous melatonin of the melatonin PRC's advance zone. Therefore, during the time interval between about CTs 14 and 1 (typically, the maximal duration of the endogenous melatonin profile), acute changes in light exposure (through its effects on endogenous melatonin levels) will affect stimulation of the melatonin PRC.
The &dquo;Overlap&dquo; Dosing Regimen
Another difference between the two PRCs is that maximal advance responses occur slightly later, at about CT 11 as compared to about CT 7. This is a somewhat surprising finding that might be the result of the one basic difference in methodologies, aside from age and gender. In the new PRC, the same amount of melatonin was administered as a single dose. In the original PRC, melatonin was administered as a split dose at these time points. The second part of the split dose was given 2 h after the first part; thus, this dosing regimen mimicked a sustained-release formulation, which would have a longer duration than a consolidated dose.
A longer duration would allow administration earlier in the afternoon while still permitting overlap of the exogenous fall with the endogenous onset. Thus, exogenous and endogenous melatonin would merge as a unitary zeitgeber, signaling an earlier increase in melatonin levels with no change in the time that they decrease. It is our thinking that the largest phase advances will be achieved by administering melatonin in the early afternoon, provided that continuity is maintained between the exogenous fall and endogenous onset; that is, if melatonin levels are discontinuous, then the magnitude of the phase shift will diminish. Consequently, the time for causing maximal advances is later with the dose of shorter duration than with the dose regimen that results in a longer duration. In preparing this review, we realized that the reason why the Zaidan et al. (1994) melatonin PRC showed a greater phase advance with a dose administered in the evening rather than in the afternoon may be that the latter did not overlap the endogenous melatonin onset.
A dosing regimen of longer duration also may be useful in stimulating more of the AUC of the appropriate (advance or delay) zone of the melatonin PRC. Sustained-release formulations, or multiple dosing regimens, may optimize phase shifting while minimizing the total dose. These maybe particularly useful when minimizing the direct soporific side effect of melatonin that appears to be related to Cmax-We recently used these ideas in treating winter depressives with melatonin. In a pilot study, we gave 5 patients an extremely low dose of melatonin (0.125 mg) at about CTs 8 and 12 (Lewy et al., in press-b) . This dosing regimen should result in physiological levels of melatonin that continue through the time of the melatonin onset and, therefore, should cause a phase advance. After the 1st and 2nd weeks of treatment, patients had twice the antidepressant response than did a group of 5 patients who received placebo capsules at these times. Despite the small sample size, the results were statistically significant.
According to the phase shift hypothesis (PSH) for winter depression , these patients become depressed in the winter at least in part because of a circadian phase delay. We and others have established that bright light scheduled in the morning (which provides a corrective phase advance) is the treatment of choice for this disorder.
However, it is not clear whether the mechanism of action for the antidepressant effect is phase advancing. If we can replicate our melatonin treatment findings in a larger group of patients with documentation of expected phase shifts, then the PSH will be substantially supported. Our past efforts to treat these patients with afternoon melatonin were unimpressive; we think the reason is that winter depressives are unusually sensitive to the soporific side effect of melatonin and were mistaking afternoon and early evening sleepiness induced by melatonin for symptoms they associate with their disorder. Given that daytime administration of melatonin frequently is the optimal time for causing phase shifting, reducing the dose to a minimum to avoid soporific side effects obviously is desirable.
In circadian phase disorders such as winter depression, small phase shifts are clinically significant. For causing larger phase shifts, optimization of dose and duration should be a fruitful area of future research. We also think that concomitant darkness with the exogenous melatonin pulse might potentiate phase shifting .
In the original melatonin PRC, we focused on the temporal relationship between the exogenous melatonin rise and the endogenous melatonin onset. It also appears to be important to consider the relationship of the exogenous melatonin pulse's rise and fall to the endogenous melatonin profile's onset and offset. For optimizing the magnitude of phase advances, the exogenous melatonin fall should overlap the endogenous onset; the earlier the rise, the greater the magnitude of phase advance (within the constraints of the melatonin PRC). Similarly, for optimizing the magnitude of phase delays, the exogenous rise should overlap the endogenous offset; the later the fall, the greater the magnitude of the phase delay We expect that this will help to achieve maximal melatonin-induced phase shifts. It may be that phase-shift magnitudes comparable to those caused by bright light may require concomitant shifts in the LD and sleep/wake cycles such as occur in shift workers , although there is no question that melatonin administration is more convenient than bright light treatment.
This review has attempted to include the most significant historic and scientific developments during the past 15 years on the phase-shifting effects of melatonin on the endogenous melatonin profile in humans, holding the LD cycle constant, as well as to try to reconcile at least some apparently inconsistent findings. Space limitations in the references prevented inclusion of many good and interesting studies. Hopefully, we presented convincing evidence that melatonin can cause phase delays as well as phase advances and that the timing of its administration is critical. In our opinion, the melatonin PRC must be taken into account whenever melatonin is given to humans.
